11:00 – CHAIR INTRODUCTION

Chair: John Campbell, Director, Tissues, Cells and Advanced Therapeutics, Scottish National Blood Transfusion Service

11:05 – PRESENTATION: Manufacturing Cellular Therapies at the Right Scale – Opportunities to Drive Efficiency and Reproducibility

• The technology in use today and what is being achieved
• What can be mechanized and what benefit would it bring?
• Manufacturing in the round – from starting materials to cryopreservation, where are the pinch points?

Speaker: John Campbell, Director, Tissues, Cells and Advanced Therapeutics, Scottish National Blood Transfusion Service

11:20 – PRESENTATION: AUTOMATION OF CGTs – FOLLOWING THE ONION PRINCIPLE

Speakers: Silvio Weber, Scientific Director, Industrial Workflow Development, Cellular Therapy, Miltenyi Biotec

11:35 – PRESENTATION: Manufacturing Automation for Early Phase ATMP Clinical Trials

• When is it appropriate to consider automation?
• Why automation early in the product development lifecycle matters

Speaker: Stuart Curbishley, Head of Business and Project Development – Advanced Therapies, University of Birmingham

11.50 – PRESENTATION: Current Cell Therapy Manufacturing Automation Challenges 

• Having sensors is not enough, you need to have access to meaningful data to be able to monitor and control the automated manufacturing processes
• Comparability between manual and automated process is key to streamline automation pathway
• High performance automated processes can be achieved by combining optimal culture environment and meaningful data

Speaker: David Horna, Co-Founder & Chief Operating Officer, Aglaris

12:05 – Panel and Q&A

Joined by: 

Stuart Curbishley, Head of Business and Project Development – Advanced Therapies, University of Birmingham

Silvio Weber, Scientific Director, Industrial Workflow Development, Cellular Therapy, Miltenyi Biotec

David Horna, Co-Founder & Chief Operating Officer, Aglaris

Toby J. Proctor, Head of Manufacturing Science & Technology, Achilles Therapeutics